Combining iRGD with HuFOLactis enhances antitumor potency by facilitating immune cell infiltration and activation

References

• Zhao D, Zhu D, Cai F, Jiang M, Liu X, Li T, Zheng Z. Current situation and prospect of adoptive cellular immunotherapy for malignancies. Technol Cancer Res Treat. 2023 Jan;22:15330338231204198. doi:10.1177/15330338231204198.
   Web of Science ®Google Scholar
• Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021 Apr 6;11(4):69. doi:10.1038/s41408-021-00459-7.
   PubMed Web of Science ®Google Scholar
• Saito S, Okuno A, Kakizaki N, Maekawa T, Tsuji NM. Lactococcus lactis subsp. cremoris C60 induces macrophages activation that enhances CD4+ T cell-based adaptive immunity. Biosci Microbiota, Food Health. 2022;41(3):130–13. doi:10.12938/bmfh.2021-057.
   PubMed Web of Science ®Google Scholar
• Zhang T, Wei X, Li Y, Huang S, Wu Y, Cai S, Aipire A, Li J. Dendritic cell-based vaccine prepared with recombinant Lactococcus lactis enhances antigen cross-presentation and antitumor efficacy through ROS production. Front Immunol. 2023;14:1208349. doi:10.3389/fimmu.2023.1208349.
   PubMed Web of Science ®Google Scholar
• Frelet-Barrand A. Lactococcus lactis, an attractive cell factory for the expression of functional membrane proteins. Biomolecules. 2022;12(2):180. doi:10.3390/biom12020180.
   PubMed Web of Science ®Google Scholar
• Kyrysyuk O, Wucherpfennig KW. Designing cancer immunotherapies that engage T cells and NK cells. Annu Rev Immunol. 2023;41(1):17–38. doi:10.1146/annurev-immunol-101921-044122.
   PubMedGoogle Scholar
• O’Neill RE, Cao X. Co-stimulatory and co-inhibitory pathways in cancer immunotherapy. Adv Cancer Res. 2019;143:145–94.
   PubMed Web of Science ®Google Scholar
• Lu X. OX40 and OX40L interaction in cancer. Curr Med Chem. 2021;28(28):5659–73. doi:10.2174/0929867328666201229123151.
   PubMed Web of Science ®Google Scholar
• Thapa B, Kato S, Nishizaki D, Miyashita H, Lee S, Nesline MK, Previs RA, Conroy JM, DePietro P, Pabla S, et al. OX40/OX40 ligand and its role in precision immune oncology. Cancer Metastasis Rev. 2024 Mar 25;1–3. doi:10.1007/s10555-024-10184-9.
   PubMed Web of Science ®Google Scholar
• Moussion C, Delamarre L. Antigen cross-presentation by dendritic cells: a critical axis in cancer immunotherapy. Semin Immunol. 2024 Feb;71:101848. doi:10.1016/j.smim.2023.101848.
   PubMed Web of Science ®Google Scholar
• Harvey AG, Graves AM, Uppalapati CK, Matthews SM, Rosenberg S, Parent EG, Fagerlie MH, Guinan J, Lopez BS, Kronstad LM, et al. Dendritic cell-natural killer cell cross-talk modulates T cell activation in response to influenza a viral infection. Front Immunol. 2022;13. doi:10.3389/fimmu.2022.1006998.
   PubMed Web of Science ®Google Scholar
• Verneau J, Sautés-Fridman C, Sun CM. Dendritic cells in the tumor microenvironment: prognostic and theranostic impact. Semin Immunol. 2020 Apr;48:101410. doi:10.1016/j.smim.2020.101410.
   PubMed Web of Science ®Google Scholar
• Waskow C, Liu K, Darrasse-Jèze G, Guermonprez P, Ginhoux F, Merad M, Shengelia T, Yao K, Nussenzweig M. The receptor tyrosine kinase Flt3 is required for dendritic cell development in peripheral lymphoid tissues. Nat Immunol. 2008 June;9(6):676–83. doi:10.1038/ni.1615.
   PubMed Web of Science ®Google Scholar
• Cueto FJ, Sancho D. The Flt3L/Flt3 axis in dendritic cell biology and cancer immunotherapy. Cancers. 2021 Mar 26;13(7):1525. doi:10.3390/cancers13071525.
   PubMed Web of Science ®Google Scholar
• Pathangey LB, McCurry DB, Gendler SJ, Dominguez AL, Gorman JE, Pathangey G, Mihalik LA, Dang Y, Disis ML, Cohen PA, et al. Surrogate in vitro activation of innate immunity synergizes with interleukin-7 to unleash rapid antigen-driven outgrowth of CD4+ and CD8+ human peripheral blood T-cells naturally recognizing MUC1, HER2/neu and other tumor-associated antigens. Oncotarget. 2017 Feb 14;8(7):10785–808. doi:10.18632/oncotarget.13911.
   PubMedGoogle Scholar
• Dong Y, Huang Y, Zhang Z, Chen A, Li L, Tian M, Shen J, Shao J. iRGD-modified memory-like NK cells exhibit potent responses to hepatocellular carcinoma. J Transl Med. 2023 Mar 17;21(1):205. doi:10.1186/s12967-023-04024-7.
   PubMed Web of Science ®Google Scholar
• Liu Q, Chu Y, Shao J, Qian H, Yang J, Sha H, Cen L, Tian M, Xu Q, Chen F, et al. Benefits of an immunogenic personalized neoantigen nanovaccine in patients with high-risk gastric/gastroesophageal junction cancer. Adv Sci (Weinheim, Baden-Wurttemberg, Ger). 2022 Nov 9;10(1):e2203298. doi:10.1002/advs.202203298.
   PubMedGoogle Scholar
• Zhou S, Meng F, Du S, Qian H, Ding N, Sha H, Zhu M, Yu X, Wang L, Liu B, et al. Bifunctional iRGD-anti-CD3 enhances antitumor potency of T cells by facilitating tumor infiltration and T-cell activation. J Immunother Cancer. 2021 May;9(5):e001925. doi:10.1136/jitc-2020-001925.
   PubMed Web of Science ®Google Scholar
• Taverniti V, Guglielmetti S. The immunomodulatory properties of probiotic microorganisms beyond their viability (ghost probiotics: proposal of paraprobiotic concept). Genes Nutr. 2011 Aug;6(3):261–74. doi:10.1007/s12263-011-0218-x.
   PubMed Web of Science ®Google Scholar
• Wang Y, Xiang Y, Xin VW, Wang X-W, Peng X-C, Liu X-Q, Wang D, Li N, Cheng J-T, Lyv Y-N, et al. Dendritic cell biology and its role in tumor immunotherapy. J Hematol Oncol. 2020 Aug 3;13(1):107. doi:10.1186/s13045-020-00939-6.
   PubMed Web of Science ®Google Scholar
• Balkwill F. Tumour necrosis factor and cancer. Nat Rev Cancer. 2009 May;9(5):361–71. doi:10.1038/nrc2628.
   PubMed Web of Science ®Google Scholar
• Zidi I, Mestiri S, Bartegi A, Amor NB. TNF-α and its inhibitors in cancer. Med Oncol (Northwood, London, England). 2010 June;27(2):185–98. doi:10.1007/s12032-009-9190-3.
   PubMed Web of Science ®Google Scholar
• Kursunel MA, Esendagli G. The untold story of IFN-γ in cancer biology. Cytokine Growth Factor Rev. 2016 Oct;31:73–81. doi:10.1016/j.cytogfr.2016.07.005.
   PubMed Web of Science ®Google Scholar
• MacNabb BW, Chen X, Tumuluru S, Godfrey J, Kasal DN, Yu J, Jongsma MLM, Spaapen RM, Kline DE, Kline J, et al. Dendritic cells can prime anti-tumor CD8+ T cell responses through major histocompatibility complex cross-dressing. Immunity. 2022;55(6):982–97.e8. doi:10.1016/j.immuni.2022.04.016.
   PubMed Web of Science ®Google Scholar
• Stojanovic A, Cerwenka A. An intimate encounter: DC3s empower anti-tumor CTLs. Cancer Cell. 2021;39(9):1181–3. doi:10.1016/j.ccell.2021.08.010.
   PubMed Web of Science ®Google Scholar
• Jacobs B, Gebel V, Heger L, Grèze V, Schild H, Dudziak D, Ullrich E. Characterization and manipulation of the crosstalk between dendritic and natural killer cells within the tumor microenvironment. Front Immunol. 2021;12:12. doi:10.3389/fimmu.2021.670540.
   Web of Science ®Google Scholar
• Bödder J, Zahan T, van Slooten R, Schreibelt G, de Vries IJM, Flórez-Grau G. Harnessing the cDC1-NK cross-talk in the tumor microenvironment to battle cancer. Front Immunol. 2021;11:11. doi:10.3389/fimmu.2020.631713.
   Web of Science ®Google Scholar
• Garris CS, Arlauckas SP, Kohler RH, Trefny MP, Garren S, Piot C, Engblom C, Pfirschke C, Siwicki M, Gungabeesoon J, et al. Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-γ and IL-12. Immunity. 2018;49(6):1148–61.e7. doi:10.1016/j.immuni.2018.09.024.
   PubMed Web of Science ®Google Scholar
• Barry KC, Hsu J, Broz ML, Cueto FJ, Binnewies M, Combes AJ, Nelson AE, Loo K, Kumar R, Rosenblum MD, et al. A natural killer–dendritic cell axis defines checkpoint therapy–responsive tumor microenvironments. Nat Med. 2018;24(8):1178–91. doi:10.1038/s41591-018-0085-8.
   PubMed Web of Science ®Google Scholar
• Ito T, Wang YH, Duramad O, Hanabuchi S, Perng OA, Gilliet M, Qin FXF, Liu Y-J. OX40 ligand shuts down IL-10-producing regulatory T cells. Proc Natl Acad Sci USA. 2006 Aug 29;103(35):13138–43. doi:10.1073/pnas.0603107103.
   PubMed Web of Science ®Google Scholar
• Kimura T, Fukushima S, Okada E, Kuriyama H, Kanemaru H, Kadohisa‐Tsuruta M, Kubo Y, Nakahara S, Tokuzumi A, Kajihara I, et al. Induced pluripotent stem cell-derived myeloid cells expressing OX40 ligand amplify antigen-specific T cells in advanced melanoma. Pigment Cell Melanoma Res. 2020 Sep;33(5):744–55. doi:10.1111/pcmr.12887.
   PubMed Web of Science ®Google Scholar
• Fromm G, de Silva S, Johannes K, Patel A, Hornblower, JC, Schreiber, TH. Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy. J Immunother Cancer. 2018 Dec 18;6(1):149. doi:10.1186/s40425-018-0454-3.
   PubMed Web of Science ®Google Scholar
• Albarrán V, San Román M, Pozas J, Chamorro J, Rosero DI, Guerrero P, Calvo JC, González C, García de Quevedo C, Pérez de Aguado P, et al. Adoptive T cell therapy for solid tumors: current landscape and future challenges. Front Immunol. 2024;15:1352805. doi:10.3389/fimmu.2024.1352805.
   PubMed Web of Science ®Google Scholar
• Zhu J, Ke Y, Liu Q, Yang J, Liu F, Xu R, Zhou H, Chen A, Xiao J, Meng F, et al. Engineered Lactococcus lactis secreting Flt3L and OX40 ligand for in situ vaccination-based cancer immunotherapy. Nat Commun. 2022 Dec 3;13(1):7466. doi:10.1038/s41467-022-35130-7.
   PubMed Web of Science ®Google Scholar
• Ding N, Zou Z, Sha H, Su S, Qian H, Meng F, Chen F, Du S, Zhou S, Chen H, et al. iRGD synergizes with PD-1 knockout immunotherapy by enhancing lymphocyte infiltration in gastric cancer. Nat Commun. 2019;10(1). doi:10.1038/s41467-019-09296-6.
   Google Scholar
• Sharma P, Goswami S, Raychaudhuri D, Siddiqui BA, Singh P, Nagarajan A, Liu J, Subudhi SK, Poon C, Gant KL, et al. Immune checkpoint therapy—current perspectives and future directions. Cell. 2023 Apr 13;186(8):1652–69. doi:10.1016/j.cell.2023.03.006.
   PubMed Web of Science ®Google Scholar